Symbols / ALGS Stock $6.47 +4.19% Aligos Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
ALGS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Lawrence M. Blatt MBA, Ph.D.
Exch · Country NCM · United States
Market Cap 40.04M
Enterprise Value -10.52M
Income -90.32M
Sales 4.71M
FCF (ttm) -49.34M
Book/sh 5.14
Cash/sh 8.87
Employees 82
Insider 10d —
IPO Oct 16, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.54
PEG —
P/S 8.51
P/B 1.26
P/C —
EV/EBITDA 0.11
EV/Sales -2.24
Quick Ratio 2.35
Current Ratio 2.56
Debt/Eq 13.69
LT Debt/Eq —
EPS (ttm) -9.78
EPS next Y -4.21
EPS Growth —
Revenue Growth 8.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -55.56%
ROE -121.86%
ROIC —
Gross Margin 0.00%
Oper. Margin -9.52%
Profit Margin 0.00%
Shs Outstand 5.39M
Shs Float 3.64M
Insider Own 10.30%
Instit Own 55.83%
Short Float 9.33%
Short Ratio 1.27
Short Interest 489.63K
52W High 13.69
vs 52W High -52.74%
52W Low 5.12
vs 52W Low 26.37%
Beta —
Impl. Vol. —
Rel Volume 0.50
Avg Volume 186.68K
Volume 93.70K
Target (mean) $65.80
Tgt Median $48.00
Tgt Low $20.00
Tgt High $175.00
# Analysts 5
Recom Strong_buy
Prev Close $6.21
Price $6.47
Change 4.19%
About

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$65.80
Mean price target
2. Current target
$6.47
Latest analyst target
3. DCF / Fair value
$-164.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.47
Low
$20.00
High
$175.00
Mean
$65.80

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-26 init WestPark Capital — → Buy $48
2026-03-11 reit HC Wainwright & Co. Buy → Buy $50
2026-01-07 init UBS — → Buy $20
2025-09-12 reit HC Wainwright & Co. Buy → Buy $50
2025-03-31 reit HC Wainwright & Co. Buy → Buy $70
2025-03-11 main HC Wainwright & Co. Buy → Buy $70
2024-11-07 reit HC Wainwright & Co. Buy → Buy $75
2024-10-23 reit HC Wainwright & Co. Buy → Buy $75
2024-09-20 reit HC Wainwright & Co. Buy → Buy $75
2024-08-19 init HC Wainwright & Co. — → Buy $75
2023-01-17 main Piper Sandler — → Overweight $7
2023-01-06 up Piper Sandler Neutral → Overweight $3
2023-01-06 up Jefferies Hold → Buy $3
2022-11-03 main SVB Leerink — → Market Perform $2
2022-05-05 down SVB Leerink Outperform → Market Perform $3
2022-03-23 main SVB Leerink — → Outperform $7
2022-03-23 down Piper Sandler Overweight → Neutral $4
2022-03-11 main Piper Sandler — → Overweight $15
2022-03-11 main SVB Leerink — → Outperform $11
2022-02-16 main SVB Leerink — → Outperform $10
News
RSS: Latest ALGS news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2.19
-44.59%
3.94
-74.60%
15.53
+11.66%
13.91
Operating Revenue
2.19
-44.59%
3.94
-74.60%
15.53
+11.66%
13.91
Operating Expense
90.17
-3.15%
93.10
-10.18%
103.66
-7.02%
111.49
Research And Development
69.45
-1.16%
70.27
-3.79%
73.04
-14.15%
85.08
Selling General And Administration
20.72
-9.25%
22.83
-25.43%
30.62
+15.93%
26.41
General And Administrative Expense
20.72
-9.25%
22.83
-25.43%
30.62
+15.93%
26.41
Other Gand A
20.72
-9.25%
22.83
-25.43%
30.62
+15.93%
26.41
Total Expenses
90.17
-3.15%
93.10
-10.18%
103.66
-7.02%
111.49
Operating Income
-87.98
+1.31%
-89.15
-1.17%
-88.13
+9.69%
-97.58
Total Operating Income As Reported
-87.98
+1.31%
-89.15
-1.17%
-88.13
+9.69%
-97.58
EBITDA
-85.18
+1.56%
-86.53
-1.73%
-85.06
+9.42%
-93.91
Normalized EBITDA
-145.36
-259.81%
-40.40
+51.26%
-82.89
+11.73%
-93.91
Reconciled Depreciation
2.81
+6.98%
2.62
-14.57%
3.07
-16.49%
3.67
EBIT
-87.98
+1.31%
-89.15
-1.17%
-88.13
+9.69%
-97.58
Total Unusual Items
60.18
+230.46%
-46.13
-2026.88%
-2.17
—
Total Unusual Items Excluding Goodwill
60.18
+230.46%
-46.13
-2026.88%
-2.17
—
Net Income
-24.19
+81.56%
-131.21
-49.65%
-87.68
+8.71%
-96.05
Pretax Income
-23.88
+81.76%
-130.88
-50.64%
-86.88
+9.44%
-95.94
Net Non Operating Interest Income Expense
3.92
-10.99%
4.41
+29.13%
3.41
+108.05%
1.64
Net Interest Income
3.92
-10.99%
4.41
+29.13%
3.41
+108.05%
1.64
Interest Income Non Operating
—
—
1.24
-24.21%
1.64
Interest Income
—
—
1.24
-24.21%
1.64
Other Income Expense
60.18
+230.46%
-46.13
-2026.88%
-2.17
—
Gain On Sale Of Security
60.18
+230.46%
-46.13
-2026.88%
-2.17
—
Tax Provision
0.31
-5.14%
0.33
-58.36%
0.80
+650.00%
0.11
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
12.64
+230.46%
-9.69
-2026.88%
-0.46
0.00
Net Income Including Noncontrolling Interests
-24.19
+81.56%
-131.21
-49.65%
-87.68
+8.71%
-96.05
Net Income From Continuing Operation Net Minority Interest
-24.19
+81.56%
-131.21
-49.65%
-87.68
+8.71%
-96.05
Net Income From Continuing And Discontinued Operation
-24.19
+81.56%
-131.21
-49.65%
-87.68
+8.71%
-96.05
Net Income Continuous Operations
-24.19
+81.56%
-131.21
-49.65%
-87.68
+8.71%
-96.05
Normalized Income
-71.74
+24.30%
-94.77
-10.24%
-85.97
+10.50%
-96.05
Net Income Common Stockholders
-24.19
+81.56%
-131.21
-49.65%
-87.68
+8.71%
-96.05
Diluted EPS
—
-20.94
+38.77%
-34.20
+39.20%
-56.25
Basic EPS
—
-20.94
+38.77%
-34.20
+39.20%
-56.25
Basic Average Shares
—
6.26
+144.38%
2.56
+50.10%
1.71
Diluted Average Shares
—
6.26
+144.38%
2.56
+50.10%
1.71
Diluted NI Availto Com Stockholders
-24.19
+81.56%
-131.21
-49.65%
-87.68
+8.71%
-96.05
Average Dilution Earnings
0.00
0.00
—
—
Total Other Finance Cost
-3.92
+10.99%
-4.41
-29.13%
-3.41
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
88.53
+26.31%
70.09
-53.74%
151.53
+3.30%
146.69
Current Assets
82.86
+33.35%
62.14
-55.95%
141.08
+5.65%
133.54
Cash Cash Equivalents And Short Term Investments
77.84
+36.71%
56.94
-58.04%
135.70
+7.85%
125.83
Cash And Cash Equivalents
18.30
-50.53%
37.00
-72.74%
135.70
+66.82%
81.35
Cash Equivalents
18.30
-50.53%
37.00
-72.74%
135.70
+66.82%
81.35
Other Short Term Investments
59.54
+198.57%
19.94
0.00
-100.00%
44.48
Restricted Cash
0.11
+0.00%
0.11
+57.14%
0.07
-39.13%
0.12
Other Current Assets
4.91
-3.61%
5.09
-4.11%
5.31
-30.16%
7.60
Total Non Current Assets
5.67
-28.69%
7.95
-23.84%
10.44
-20.57%
13.15
Net PPE
4.96
-32.35%
7.33
-25.38%
9.82
-21.54%
12.51
Gross PPE
17.67
-7.54%
19.11
-7.12%
20.57
-6.83%
22.08
Accumulated Depreciation
-12.71
-7.89%
-11.78
-9.55%
-10.76
-12.41%
-9.57
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.11
+2.03%
2.06
-0.72%
2.08
-0.81%
2.10
Construction In Progress
0.00
-100.00%
0.00
+0.00%
0.00
-81.82%
0.02
Other Properties
9.30
-15.00%
10.94
-11.70%
12.39
-10.72%
13.88
Leases
6.26
+2.67%
6.10
+0.00%
6.10
+0.23%
6.09
Investments And Advances
—
—
—
0.00
Other Non Current Assets
0.71
+14.04%
0.63
+0.32%
0.62
-1.42%
0.63
Total Liabilities Net Minority Interest
34.99
-64.68%
99.07
+66.65%
59.45
+38.92%
42.79
Current Liabilities
21.23
-2.32%
21.74
-9.07%
23.91
-27.84%
33.13
Payables And Accrued Expenses
10.04
-14.45%
11.74
-7.45%
12.69
-11.98%
14.41
Payables
3.98
+54.88%
2.57
-15.09%
3.03
-76.60%
12.94
Accounts Payable
3.98
+54.88%
2.57
+2.15%
2.52
-46.87%
4.74
Other Payable
—
1.47
+187.87%
0.51
-93.77%
8.20
Current Accrued Expenses
6.06
-33.89%
9.17
-5.05%
9.66
+555.67%
1.47
Pensionand Other Post Retirement Benefit Plans Current
7.46
+16.86%
6.39
-4.29%
6.67
+5.97%
6.30
Current Debt And Capital Lease Obligation
3.73
+7.72%
3.46
+6.76%
3.24
+3.05%
3.14
Current Capital Lease Obligation
3.73
+7.72%
3.46
+6.76%
3.24
+3.05%
3.14
Current Deferred Liabilities
0.00
-100.00%
0.15
-88.46%
1.31
-85.80%
9.21
Current Deferred Revenue
0.00
-100.00%
0.15
-88.46%
1.31
-85.80%
9.21
Other Current Liabilities
—
—
—
0.07
Total Non Current Liabilities Net Minority Interest
13.76
-82.21%
77.33
+117.58%
35.54
+267.77%
9.66
Long Term Debt And Capital Lease Obligation
1.52
-68.99%
4.92
-37.75%
7.90
-16.24%
9.43
Long Term Capital Lease Obligation
1.52
-68.99%
4.92
-37.75%
7.90
-16.24%
9.43
Non Current Deferred Liabilities
—
—
0.00
-100.00%
0.23
Non Current Deferred Revenue
—
—
0.00
-100.00%
0.23
Other Non Current Liabilities
0.05
+2.17%
0.05
+0.00%
0.05
—
Stockholders Equity
53.55
+284.81%
-28.97
-131.47%
92.08
-11.38%
103.90
Common Stock Equity
53.55
+284.81%
-28.97
-131.47%
92.08
-11.38%
103.90
Capital Stock
0.01
+12.50%
0.01
+14.29%
0.01
+75.00%
0.00
Common Stock
0.01
+12.50%
0.01
+14.29%
0.01
+75.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
6.18
+59.87%
3.86
+28.65%
3.00
+74.96%
1.72
Ordinary Shares Number
6.18
+59.87%
3.86
+28.65%
3.00
+74.96%
1.72
Additional Paid In Capital
695.27
+18.13%
588.58
+1.77%
578.33
+15.06%
502.61
Retained Earnings
-642.20
-3.91%
-618.01
-26.95%
-486.80
-21.97%
-399.12
Gains Losses Not Affecting Retained Earnings
0.47
+3.77%
0.45
-17.25%
0.55
+35.91%
0.40
Other Equity Adjustments
0.47
+3.77%
0.45
-17.25%
0.55
+35.91%
0.40
Total Equity Gross Minority Interest
53.55
+284.81%
-28.97
-131.47%
92.08
-11.38%
103.90
Total Capitalization
53.55
+284.81%
-28.97
-131.47%
92.08
-11.38%
103.90
Working Capital
61.63
+52.53%
40.40
-65.52%
117.18
+16.69%
100.42
Invested Capital
53.55
+284.81%
-28.97
-131.47%
92.08
-11.38%
103.90
Total Debt
5.25
-37.31%
8.38
-24.81%
11.14
-11.42%
12.57
Capital Lease Obligations
5.25
-37.31%
8.38
-24.81%
11.14
-11.42%
12.57
Net Tangible Assets
53.55
+284.81%
-28.97
-131.47%
92.08
-11.38%
103.90
Tangible Book Value
53.55
+284.81%
-28.97
-131.47%
92.08
-11.38%
103.90
Available For Sale Securities
—
—
—
—
Derivative Product Liabilities
12.18
-83.16%
72.37
+162.24%
27.60
0.00
Investmentin Financial Assets
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-82.50
-2.18%
-80.74
-2.21%
-79.00
+0.49%
-79.39
Cash Flow From Continuing Operating Activities
-82.50
-2.18%
-80.74
-2.21%
-79.00
+0.49%
-79.39
Net Income From Continuing Operations
-24.19
+81.56%
-131.21
-49.65%
-87.68
+8.71%
-96.05
Depreciation Amortization Depletion
2.81
+6.98%
2.62
-14.57%
3.07
-16.49%
3.67
Depreciation
2.81
+6.98%
2.62
-14.57%
3.07
-16.49%
3.67
Depreciation And Amortization
2.81
+6.98%
2.62
-14.57%
3.07
-16.49%
3.67
Stock Based Compensation
5.04
-40.32%
8.45
-33.20%
12.65
-13.89%
14.69
Asset Impairment Charge
—
0.00
-100.00%
0.72
0.00
Operating Gains Losses
-60.18
-230.46%
46.13
+2010.34%
2.19
—
Gain Loss On Investment Securities
-60.18
-230.46%
46.13
+2026.88%
2.17
—
Change In Working Capital
-3.79
+23.57%
-4.96
+47.98%
-9.53
-513.72%
-1.55
Change In Payables And Accrued Expense
-0.62
+53.52%
-1.33
-2.54%
-1.30
+82.46%
-7.42
Change In Accrued Expense
-2.03
-46.33%
-1.39
-251.20%
0.92
+110.04%
-9.14
Change In Payable
1.41
+2512.96%
0.05
+102.43%
-2.22
-228.86%
1.72
Change In Account Payable
1.41
+2512.96%
0.05
+102.43%
-2.22
-228.86%
1.72
Change In Other Working Capital
-0.15
+86.95%
-1.16
+85.78%
-8.13
-425.14%
2.50
Change In Other Current Assets
0.10
-55.56%
0.22
-90.60%
2.30
-56.79%
5.32
Change In Other Current Liabilities
-3.11
-16.12%
-2.68
-12.32%
-2.39
-22.23%
-1.95
Investing Cash Flow
-37.83
-106.94%
-18.28
-140.64%
44.98
+271.08%
-26.29
Cash Flow From Continuing Investing Activities
-37.83
-106.94%
-18.28
-140.64%
44.98
+271.08%
-26.29
Net PPE Purchase And Sale
-0.44
-236.15%
-0.13
-584.21%
-0.02
+97.99%
-0.94
Purchase Of PPE
-0.44
-236.15%
-0.13
-584.21%
-0.02
+97.99%
-0.94
Capital Expenditure
-0.44
-236.15%
-0.13
-584.21%
-0.02
+97.99%
-0.94
Net Investment Purchase And Sale
-37.39
-106.01%
-18.15
-140.33%
45.00
+277.51%
-25.35
Purchase Of Investment
-164.89
-52.46%
-108.15
-983072.73%
-0.01
+99.99%
-104.27
Sale Of Investment
127.50
+41.67%
90.00
+99.95%
45.01
-42.96%
78.92
Financing Cash Flow
101.64
+28529.58%
0.35
-99.60%
88.33
+53758.54%
0.16
Cash Flow From Continuing Financing Activities
101.64
+28529.58%
0.35
-99.60%
88.33
+53758.54%
0.16
Net Issuance Payments Of Debt
-0.01
+83.13%
-0.08
+13.54%
-0.10
-57.38%
-0.06
Repayment Of Debt
-0.01
+83.13%
-0.08
+13.54%
-0.10
-57.38%
-0.06
Long Term Debt Payments
-0.01
+83.13%
-0.08
+13.54%
-0.10
-57.38%
-0.06
Net Long Term Debt Issuance
-0.01
+83.13%
-0.08
+13.54%
-0.10
-57.38%
-0.06
Net Common Stock Issuance
101.34
0.00
-100.00%
17.44
0.00
Proceeds From Stock Option Exercised
0.30
-30.59%
0.44
-99.38%
70.98
+31447.11%
0.23
Net Other Financing Charges
—
—
—
—
Changes In Cash
-18.69
+81.05%
-98.67
-281.67%
54.31
+151.47%
-105.52
Beginning Cash Position
37.11
-72.67%
135.77
+66.67%
81.46
-56.43%
186.98
End Cash Position
18.41
-50.38%
37.11
-72.67%
135.77
+66.67%
81.46
Free Cash Flow
-82.94
-2.56%
-80.87
-2.35%
-79.02
+1.64%
-80.33
Interest Paid Supplemental Data
—
—
—
0.00
Income Tax Paid Supplemental Data
—
—
—
0.00
Amortization Of Securities
-2.19
-22.71%
-1.78
-320.52%
-0.42
-166.67%
-0.16
Common Stock Issuance
101.34
0.00
-100.00%
17.44
0.00
Issuance Of Capital Stock
101.34
0.00
-100.00%
17.44
0.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category